156 related articles for article (PubMed ID: 27282741)
41. Intramolecular C - N bond formation under metal-free conditions: synthesis of indolizines.
Wu J; Leng WL; Liao H; Mai Hoang KL; Liu XW
Chem Asian J; 2015 Apr; 10(4):853-6. PubMed ID: 25643670
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and biological evaluation of indolyl chalcones as antitumor agents.
Kumar D; Kumar NM; Akamatsu K; Kusaka E; Harada H; Ito T
Bioorg Med Chem Lett; 2010 Jul; 20(13):3916-9. PubMed ID: 20627724
[TBL] [Abstract][Full Text] [Related]
43. Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors.
Seo WD; Kim JH; Kang JE; Ryu HW; Curtis-Long MJ; Lee HS; Yang MS; Park KH
Bioorg Med Chem Lett; 2005 Dec; 15(24):5514-6. PubMed ID: 16202584
[TBL] [Abstract][Full Text] [Related]
44. Synthetic chalcones and sulfonamides as new classes of Yersinia enterocolitica YopH tyrosine phosphatase inhibitors.
Martins PG; Menegatti AC; Chiaradia-Delatorre LD; de Oliveira KN; Guido RV; Andricopulo AD; Vernal J; Yunes RA; Nunes RJ; Terenzi H
Eur J Med Chem; 2013 Jun; 64():35-41. PubMed ID: 23639652
[TBL] [Abstract][Full Text] [Related]
45. Synthesis, characterization and biological evaluation of anti-cancer indolizine derivatives via inhibiting β-catenin activity and activating p53.
Moon SH; Jung Y; Kim SH; Kim I
Bioorg Med Chem Lett; 2016 Jan; 26(1):110-3. PubMed ID: 26608553
[TBL] [Abstract][Full Text] [Related]
46. Studies on indolizines. Evaluation of their biological properties as microtubule-interacting agents and as melanoma targeting compounds.
Ghinet A; Abuhaie CM; Gautret P; Rigo B; Dubois J; Farce A; Belei D; Bîcu E
Eur J Med Chem; 2015 Jan; 89():115-27. PubMed ID: 25462232
[TBL] [Abstract][Full Text] [Related]
47. Surfing the piperazine core of tricyclic farnesyltransferase inhibitors.
Rokosz LL; Huang CY; Reader JC; Stauffer TM; Chelsky D; Sigal NH; Ganguly AK; Baldwin JJ
Bioorg Med Chem Lett; 2005 Dec; 15(24):5537-43. PubMed ID: 16202593
[TBL] [Abstract][Full Text] [Related]
48. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
[TBL] [Abstract][Full Text] [Related]
49. Design and synthesis of a new type of non steroidal human aromatase inhibitors.
Sonnet P; Guillon J; Enguehard C; Dallemagne P; Bureau R; Rault S Auvray P; Moslemi S; Sourdiane P; Galopin S; Séralini GE
Bioorg Med Chem Lett; 1998 May; 8(9):1041-4. PubMed ID: 9871704
[TBL] [Abstract][Full Text] [Related]
50. Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zarnestra series.
Angibaud P; Mevellec L; Meyer C; Bourdrez X; Lezouret P; Pilatte I; Poncelet V; Roux B; Merillon S; End DW; Van Dun J; Wouters W; Venet M
Eur J Med Chem; 2007 May; 42(5):702-14. PubMed ID: 17316920
[TBL] [Abstract][Full Text] [Related]
51. Analogues of xanthones--Chalcones and bis-chalcones as α-glucosidase inhibitors and anti-diabetes candidates.
Cai CY; Rao L; Rao Y; Guo JX; Xiao ZZ; Cao JY; Huang ZS; Wang B
Eur J Med Chem; 2017 Apr; 130():51-59. PubMed ID: 28242551
[TBL] [Abstract][Full Text] [Related]
52. Indolizine 1-sulfonates as potent inhibitors of 15-lipoxygenase from soybeans.
Teklu S; Gundersen LL; Larsen T; Malterud KE; Rise F
Bioorg Med Chem; 2005 May; 13(9):3127-39. PubMed ID: 15809148
[TBL] [Abstract][Full Text] [Related]
53. New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis.
Lethu S; Bosc D; Mouray E; Grellier P; Dubois J
J Enzyme Inhib Med Chem; 2013 Feb; 28(1):163-71. PubMed ID: 22233543
[TBL] [Abstract][Full Text] [Related]
54. vHTS and 3D-QSAR for the Identification of Novel Phyto-inhibitors of Farnesyltransferase: Validation of Ascorbic Acid inhibition of Farnesyltransferase in an Animal Model of Breast Cancer.
Samuel Metibemu D
Drug Res (Stuttg); 2021 Jul; 71(6):341-347. PubMed ID: 33862663
[TBL] [Abstract][Full Text] [Related]
55. Synthesis, α-glucosidase inhibitory and molecular docking studies of prenylated and geranylated flavones, isoflavones and chalcones.
Sun H; Li Y; Zhang X; Lei Y; Ding W; Zhao X; Wang H; Song X; Yao Q; Zhang Y; Ma Y; Wang R; Zhu T; Yu P
Bioorg Med Chem Lett; 2015 Oct; 25(20):4567-71. PubMed ID: 26351039
[TBL] [Abstract][Full Text] [Related]
56. Farnesyltransferase inhibitors: CAAX mimetics based on different biaryl scaffolds.
Straniero V; Pallavicini M; Chiodini G; Ruggeri P; Fumagalli L; Bolchi C; Corsini A; Ferri N; Ricci C; Valoti E
Bioorg Med Chem Lett; 2014 Jul; 24(13):2924-7. PubMed ID: 24821376
[TBL] [Abstract][Full Text] [Related]
57. Chalcones, inhibitors for topoisomerase I and cathepsin B and L, as potential anti-cancer agents.
Kim SH; Lee E; Baek KH; Kwon HB; Woo H; Lee ES; Kwon Y; Na Y
Bioorg Med Chem Lett; 2013 Jun; 23(11):3320-4. PubMed ID: 23608763
[TBL] [Abstract][Full Text] [Related]
58. Design, Synthesis and Biological Evaluation of Oxindole-Based Chalcones as Small-Molecule Inhibitors of Melanogenic Tyrosinase.
Suthar SK; Bansal S; Narkhede N; Guleria M; Alex AT; Joseph A
Chem Pharm Bull (Tokyo); 2017; 65(9):833-839. PubMed ID: 28867710
[TBL] [Abstract][Full Text] [Related]
59. Guiding farnesyltransferase inhibitors from an ECLiPS library to the catalytic zinc.
Huang CY; Stauffer TM; Strickland CL; Reader JC; Huang H; Li G; Cooper AB; Doll RJ; Ganguly AK; Baldwin JJ; Rokosz LL
Bioorg Med Chem Lett; 2006 Feb; 16(3):507-11. PubMed ID: 16289818
[TBL] [Abstract][Full Text] [Related]
60. Effect of Farnesyltransferase Inhibitor R115777 on Mitochondria of Plasmodium falciparum.
Ha YR; Hwang BG; Hong Y; Yang HW; Lee SJ
Korean J Parasitol; 2015 Aug; 53(4):421-30. PubMed ID: 26323840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
